Ceapro Inc (CZO):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C10028)
◆英語タイトル:Ceapro Inc (CZO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10028
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:39
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥55,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥82,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Ceapro Inc (Ceapro) is a biotechnology company which develops proprietary extraction technologies for use in the production of extracts and active ingredients from oats and other renewable plant resources. The company’s extracts are also used in nutraceutical, cosmeceutical, and therapeutics products for humans and animals. Ceapro’s portfolio includes natural active ingredients comprising oat avenanthramides, oat oil, oat peptides, oat beta glucan, and lupin peptides; and veterinary products including oat shampoo, ear cleanser and dermal complex/conditioner. The company offers its products in Canada, United States, Germany, China and other countries. Ceapro is headquartered in Edmonton, Alberta, Canada.

Ceapro Inc (CZO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Ceapro Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ceapro Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Ceapro Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ceapro Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Ceapro Inc, Medical Devices Deals, 2012 to YTD 2018 9
Ceapro Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Ceapro Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Ceapro Enters into Agreement with Montreal Heart Institute 11
Licensing Agreements 12
Ceapro Expands Licensing Agreement with University of Alberta 12
Symrise Enters Into Licensing Agreement With Ceapro 13
Equity Offering 14
Ceapro Raises USD3.3 Million in Second and Final Tranche of Private Placement of Units 14
Ceapro Raises USD4.4 Million in First Tranche of Brokered Private Placement of Units 16
Debt Offering 18
Ceapro Raises USD0.24 Million in Second Tranche of Private Placement of Debentures Due 2016 18
Ceapro Inc – Key Competitors 19
Ceapro Inc – Key Employees 20
Ceapro Inc – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Financial Announcements 22
Aug 28, 2018: Ceapro reports 2018 second quarter and six-month financial results and operational highlights 22
May 17, 2018: Ceapro Announces 2018 First Quarter Results 23
Apr 20, 2018: Ceapro Reports 2017 Financial Results 24
Nov 15, 2017: Ceapro Reports 2017 Third Quarter Business Update and Financial Results 25
Aug 18, 2017: Ceapro Reports 2017 Second Quarter Business Update and Financial Results 27
May 17, 2017: Ceapro Reports 2017 First Quarter Development Highlights and Financial Results 29
Apr 06, 2017: Ceapro Reports 2016 Financial Results and Provides Corporate Update 31
Legal and Regulatory 33
Aug 27, 2018: Ceapro settles judgements in AVAC actions 33
Product News 34
May 29, 2018: Ceapro Confirms Excellent Bioavailability of its New Water Soluble Chemical Complex Coenzyme Q10-Beta Glucan 34
Other Significant Developments 36
Apr 23, 2018: Ceapro Provides Corporate Update – Company well poised to transition to its next phase of growth for expansion into the profitable nutraceutical sector 36
Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39

List of Tables
Ceapro Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Ceapro Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ceapro Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Ceapro Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ceapro Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Ceapro Inc, Medical Devices Deals, 2012 to YTD 2018 9
Ceapro Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Ceapro Enters into Agreement with Montreal Heart Institute 11
Ceapro Expands Licensing Agreement with University of Alberta 12
Symrise Enters Into Licensing Agreement With Ceapro 13
Ceapro Raises USD3.3 Million in Second and Final Tranche of Private Placement of Units 14
Ceapro Raises USD4.4 Million in First Tranche of Brokered Private Placement of Units 16
Ceapro Raises USD0.24 Million in Second Tranche of Private Placement of Debentures Due 2016 18
Ceapro Inc, Key Competitors 19
Ceapro Inc, Key Employees 20
Ceapro Inc, Subsidiaries 21

List of Figures
Ceapro Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ceapro Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ceapro Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ceapro Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ceapro Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ceapro Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Ceapro Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ceapro Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Ceapro Inc, Medical Devices Deals, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Ceapro Inc (CZO):製薬・医療:M&Aディール及び事業提携情報(Ceapro Inc (CZO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆